StratifAI is an innovative Berlin-based precision oncology startup developing the next generation of AI-based cancer biomarkers. The founders have published over 100 articles in top-tier journals and founded StratifAI to translate these novel ideas into patient care.
Our products enable cancer patients to receive the right treatment at the right time - both for existing drugs on the market, and by supporting pharmaceutical companies in developing the drugs of tomorrow.